Novimmune Opens Branch Office in Basel
The Basel office will house the clinical development team and other functions to progress the company’s lead compound emapalumab.
Swiss biotech company, Novimmune, has opened a branch office in Basel, Switzerland. Novimmune specializes in the development of antibody-based drugs. The Basel office at Dufourstrasse 11 will house the clinical development team and other functions to progress the company’s lead compound emapalumab. Novimmune is working towards a regulatory filing for marketing authorization and hopes to launch the product in Europe and the United States.
Emapalumab (NI-0501) is currently undergoing phase 2/3 evalution for the treatment of primary hemophagocytic lymphohistiocytosis, a life-threatening disease of severe hyperinflammation, which mainly affects children. In June 2016, the drug was granted priority medicine status by the European Medicines Agency (EMA), just three months after the US Food and Drug Administration (FDA) had approved its breakthrough therapy designation.
Source: Novimmune
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Pfizer Obtains Exclusive Rights to 3SBio’s Bispecific Antibody Targeting PD-1 and VEGF
July 31st 2025The licensing agreement between the two companies gives Pfizer the rights to develop, manufacture, and commercialize 3SBio’s bispecific antibody, SSGJ-707, which is in clinical trials for the treatment of a variety of cancers.
